CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 228 enrolled
Drug / intervention
Lebrikizumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04250337
NCT04250337Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company·interventional·Posted Jan 31, 2020·Updated May 9, 2022

In Brief

A Phase 3 clinical trial evaluating Lebrikizumab, Placebo, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 228 participants across 63 sites in 4 countries.

Detailed Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, Germany, Poland, United States
CollaboratorsDermira, Inc.

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 31, 2020
Enrollment StartFeb 3, 2020
Primary CompletionAug 11, 2021
Study CompletionSep 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.4 years ago

Interventions

Lebrikizumabbiological

Subcutaneous injection

Placeboother

Subcutaneous injection

Topical Corticosteroidother

Topical Corticosteroid